Lung Cancer Clinical Trial
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Summary
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Full Description
This is a Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC).
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation
No prior chemotherapy or any other systemic therapy for metastatic NSCLC
Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred >12 months from end of last therapy
Known tumor PD-L1 status
Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care
WHO/ECOG status at 0 or 1 at enrollment
Life expectancy of at least 12 weeks
Troponin I or T ≤ ULN (per institutional guidelines)
Exclusion Criteria:
Active or prior documented autoimmune or inflammatory disorders
History of active primary immunodeficiency
Any prior chemotherapy or any other systemic therapy for metastatic NSCLC
Untreated CNS metastases
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 45 Locations for this study
Iowa City Iowa, 52242, United States
Pittsburgh Pennsylvania, 15212, United States
Nashville Tennessee, 37203, United States
Salzburg , 5020, Austria
Wien , 1140, Austria
Edegem , 2650, Belgium
Edmonton Alberta, T6G 1, Canada
Toronto , M5G 2, Canada
Cheongju-si , 28644, Korea, Republic of
Seoul , 03080, Korea, Republic of
Seoul , 03722, Korea, Republic of
Seoul , 05505, Korea, Republic of
Seoul , 06351, Korea, Republic of
Bialystok , 15-02, Poland
Bydgoszcz , 85-79, Poland
Gdańsk , 80-21, Poland
GrudziÄ…dz , 86-30, Poland
Olsztyn , 10-35, Poland
Poznan , 60-69, Poland
Tomaszów Mazowiecki , 97-20, Poland
Warszawa , 02-78, Poland
Wroclaw , 53-41, Poland
Åódź , 90-30, Poland
Krasnoyarsk , 66013, Russian Federation
Moscow , 11547, Russian Federation
Saint Petersburg , 19775, Russian Federation
Sankt-Peterburg , 19775, Russian Federation
St.Petersburg , 19101, Russian Federation
Barcelona , 08025, Spain
Barcelona , 08035, Spain
Barcelona , 8003, Spain
Madrid , 28034, Spain
Madrid , 28041, Spain
Sevilla , 41013, Spain
Kaohsiung , 807, Taiwan
Taichung City , 402, Taiwan
Taichung , 40705, Taiwan
Tainan City , 70403, Taiwan
Taipei , 10002, Taiwan
Taipei , 112, Taiwan
Taipei , 235, Taiwan
Taoyuan , 333, Taiwan
Bangkok , 10330, Thailand
Bangkok , 10700, Thailand
Chiang Mai , 50200, Thailand
Hat Yai , 90110, Thailand
How clear is this clinincal trial information?